18:29:07 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Nordic Nanovector är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo.

Kalender

2022-11-10 Kvartalsrapport 2022-Q3
2022-07-20 Kvartalsrapport 2022-Q2
2022-05-13 Kvartalsrapport 2022-Q1
2022-04-28 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2022-02-14 Extra Bolagsstämma 2022
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning NANOV 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning NANOV 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning NANOV 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NANOV 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning NANOV 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning NANOV 0.00 NOK
2016-05-19 Kvartalsrapport 2016-Q1
2016-05-19 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014
2020-12-01 07:30:14
Oslo, Norway, 1 December 2020<br />
<br />
Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment
into<br />
the LYMRIT 37-05 Phase 1 clinical trial of Betalutin[®] ([177]Lu lilotomab<br />
satetraxetan) in patients with relapsed/refractory diffuse large B-cell
lymphoma<br />
(R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT).<br />
<br />
Eighteen DLBCL patients were enrolled into the trial at clinical trial sites
in<br />
the US and Europe and were dosed with three escalating treatment doses of<br />
Betalutin[®] (10MBq/kg, 15MBq/kg and 20MBq/kg). A preliminary data readout is<br
/>
expected in H1'2021.<br />
<br />
As announced in April 2020, LYMRIT 37-05 will be paused pending analysis of<br
/>
these data, which is expected to inform plans for the further development of<br
/>
Betalutin[®] in R/R DLBCL.<br />
<br />
Nordic Nanovector's primary focus is the timely completion of the pivotal
Phase<br />
2b PARADIGME trial of Betalutin[®] in 3rd-line follicular lymphoma (3L FL).<br
/>
<br />
Christine Wilkinson Blanc, Chief Medical Officer of Nordic Nanovector, said:<br
/>
"The completion of recruitment into this dose-finding study in patients with<br
/>
DLBCL is an important milestone. DLBCL remains a significant indication with
a<br />
large unmet medical need. The data analysis from this trial will form the
basis<br />
of our considerations for the further development of Betalutin[®] in DLBCL
and<br />
more broadly across non-Hodgkin's lymphoma."<br />
<br />
The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation<br
/>
study in DLBCL designed to determine the dose to be recommended for further<br
/>
studies in DLBCL and assess the safety, tolerability, pharmacokinetic profile<br
/>
and preliminary anti-tumour activity of a single administration of
Betalutin[®].<br />
More information on this study can be found at www.clinicaltrials.gov<br />
(NCT02658968).<br />
<br />
DLBCL is an aggressive form of non-Hodgkin's Lymphoma (NHL) that accounts for<br
/>
30% of all NHL cases[1,2]. The number of diagnosed incident cases of DLBCL in<br
/>
the seven major markets (US, key five European markets and Japan) was 64,172
in<br />
2018 and is expected to grow to 74,927 in 2028[3].<br />
<br />
Approximately 40% of DLBCL patients relapse after first-line combination<br />
treatment with rituximab and chemotherapy. These patients have few
therapeutic<br />
options, with high-dose chemotherapy and autologous stem cell transplant
(ASCT)<br />
achieving long-term remissions in only a minority of patients[4]. Relapsed
DLBCL<br />
therefore remains a serious unmet medical need.<br />
<br />
References<br />
<br />
1. Siegel R, Miller K and Jemal A. Cancer Statistics, 2019. CA Cancer J.
Clin.<br />
2019